Acquired by Pharmacosmos Group in Oct 2024
GTHX - G1 Therapeutics, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Research Triangle Park,
United States
Type: Equity
GTHX price evolution
GTHX
| (in millions $) | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $15.32 | $20.14 | $32.47 | $52.87 |
| Short term investments | $45.66 | $45.3 | $49.94 | $41.73 |
| Net receivables | $13.31 | $11.65 | $12.69 | $9.27 |
| Inventory | $13.38 | $12.55 | $12.44 | $13.49 |
| Total current assets | $92.92 | $95.84 | $114.95 | $126.1 |
| Long term investments | ||||
| Property, plant & equipment | $5.58 | $5.99 | $6.38 | $6.78 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $5.77 | $6.19 | $6.59 | $6.99 |
| Total investments | $45.66 | $45.3 | $49.94 | $41.73 |
| Total assets | $98.69 | $102.03 | $121.54 | $133.1 |
| Current liabilities | ||||
| Accounts payable | $5.16 | $5.11 | $3.99 | $7.33 |
| Deferred revenue | $0.95 | $0.9 | $1.12 | $1.19 |
| Short long term debt | $11.41 | $5.95 | ||
| Total current liabilities | $37.5 | $32.6 | $29.72 | $33.65 |
| Long term debt | $36.55 | $41.14 | $55.9 | $55.92 |
| Total noncurrent liabilities | $36.59 | $41.68 | $56.44 | $56.42 |
| Total debt | $47.96 | $47.09 | $55.9 | $55.92 |
| Total liabilities | $74.1 | $74.29 | $86.15 | $90.08 |
| Shareholders' equity | ||||
| Retained earnings | -$795.67 | -$790.2 | -$779.99 | -$769.11 |
| Other shareholder equity | ||||
| Total shareholder equity | $24.59 | $27.74 | $35.39 | $43.02 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $32.47 | $94.91 | $221.56 | $207.81 |
| Short term investments | $49.94 | $50.48 | ||
| Net receivables | $12.69 | $11.09 | $5.69 | $0.24 |
| Inventory | $12.44 | $16.18 | $3.47 | |
| Total current assets | $114.95 | $179.5 | $243.56 | $216.39 |
| Long term investments | ||||
| Property, plant & equipment | $6.38 | $7.95 | $9.05 | $10.51 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $6.59 | $8.46 | $10.53 | $12.16 |
| Total investments | $49.94 | $50.48 | ||
| Total assets | $121.54 | $187.97 | $254.09 | $228.55 |
| Current liabilities | ||||
| Accounts payable | $3.99 | $7.43 | $2.9 | $3.57 |
| Deferred revenue | $1.12 | $1.01 | $1.03 | $0.24 |
| Short long term debt | ||||
| Total current liabilities | $29.72 | $35.59 | $27.61 | $23.44 |
| Long term debt | $55.9 | $77.02 | $81.94 | $27.76 |
| Total noncurrent liabilities | $56.44 | $83.63 | $82.94 | $27.76 |
| Total debt | $55.9 | $82.63 | $81.94 | $27.76 |
| Total liabilities | $86.15 | $119.22 | $110.55 | $51.2 |
| Shareholders' equity | ||||
| Retained earnings | -$779.99 | -$732.02 | -$584.46 | -$436.11 |
| Other shareholder equity | -$0.01 | |||
| Total shareholder equity | $35.39 | $68.75 | $143.54 | $177.35 |
| (in millions $) | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $16.55 | $14.48 | $14.87 | $12.3 |
| Cost of revenue | $0.73 | $1.08 | $1.26 | $3.08 |
| Gross Profit | $15.81 | $13.4 | $13.62 | $9.22 |
| Operating activities | ||||
| Research & development | $5.74 | $7.32 | $7.38 | $8.81 |
| Selling, general & administrative | $13.61 | $15.13 | $15.17 | $16.78 |
| Total operating expenses | $19.35 | $22.45 | $22.55 | $25.59 |
| Operating income | -$3.54 | -$9.05 | -$8.93 | -$16.37 |
| Income from continuing operations | ||||
| EBIT | -$2.74 | -$8.24 | -$7.85 | -$15.18 |
| Income tax expense | $0.9 | $0.91 | ||
| Interest expense | $2.73 | $1.98 | $2.12 | $2.12 |
| Net income | ||||
| Net income | -$5.47 | -$10.22 | -$10.88 | -$18.2 |
| Income (for common shares) | -$5.47 | -$10.22 | -$10.88 | -$18.2 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $82.51 | $51.3 | $31.48 | $45.28 |
| Cost of revenue | $7.2 | $3.75 | $2.02 | |
| Gross Profit | $75.32 | $47.55 | $29.46 | $45.28 |
| Operating activities | ||||
| Research & development | $43.71 | $83.32 | $76.22 | $73.27 |
| Selling, general & administrative | $71.13 | $100.42 | $95.69 | $68.49 |
| Total operating expenses | $114.84 | $183.73 | $171.92 | $141.76 |
| Operating income | -$39.53 | -$136.18 | -$142.46 | -$96.48 |
| Income from continuing operations | ||||
| EBIT | -$34.81 | -$135.43 | -$142.76 | -$96.07 |
| Income tax expense | $3.12 | $1.7 | $0.93 | $1.41 |
| Interest expense | $10.04 | $10.43 | $4.67 | $1.78 |
| Net income | ||||
| Net income | -$47.97 | -$147.56 | -$148.35 | -$99.25 |
| Income (for common shares) | -$47.97 | -$147.56 | -$148.35 | -$99.25 |
| (in millions $) | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 |
|---|---|---|---|---|
| Net income | -$5.47 | -$10.22 | -$10.88 | -$18.2 |
| Operating activities | ||||
| Depreciation | $0.12 | $0.12 | $0.12 | $0.13 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $2.09 | $2.55 | $3.21 | $3.65 |
| Total cash flows from operations | -$5.27 | -$8.9 | -$12.79 | -$10.58 |
| Investing activities | ||||
| Capital expenditures | $0 | |||
| Investments | $0.23 | $5.29 | -$7.65 | $7.2 |
| Total cash flows from investing | $0.23 | $5.29 | -$7.65 | $7.2 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.23 | $0.03 | $0.03 | $0.02 |
| Net borrowings | -$8.75 | $0 | -$0 | |
| Total cash flows from financing | $0.23 | -$8.72 | $0.03 | $0.02 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$4.81 | -$12.33 | -$20.41 | -$3.35 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$47.97 | -$147.56 | -$148.35 | -$99.25 |
| Operating activities | ||||
| Depreciation | $0.51 | $0.53 | $0.47 | $0.58 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $14.51 | $20.59 | $22.32 | $18.77 |
| Total cash flows from operations | -$38.34 | -$128.62 | -$132.11 | -$83.74 |
| Investing activities | ||||
| Capital expenditures | -$0.51 | $0.15 | ||
| Investments | $2.81 | -$50.02 | ||
| Total cash flows from investing | $2.81 | -$50.53 | $0.15 | |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.06 | $52.54 | $92.27 | $2.31 |
| Net borrowings | -$26.69 | $53.64 | $19.38 | |
| Total cash flows from financing | -$26.91 | $52.49 | $145.86 | $21.69 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$62.44 | -$126.65 | $13.76 | -$61.9 |
News
Fundamentals
| Market cap | $376.79M |
|---|---|
| Enterprise value | $409.43M |
| Shares outstanding | 52.70M |
| Revenue | $58.20M |
|---|---|
| EBITDA | -$33.53M |
| EBIT | -$34.02M |
| Net Income | -$44.77M |
| Revenue Q/Q | -60.97% |
| Revenue Y/Y | -34.73% |
| P/E ratio | -8.42 |
|---|---|
| EV/Sales | 7.04 |
| EV/EBITDA | -12.21 |
| EV/EBIT | -12.03 |
| P/S ratio | 6.47 |
| P/B ratio | 15.32 |
| Book/Share | 0.47 |
| Cash/Share | 0.29 |
| EPS | -$0.85 |
|---|---|
| ROA | -39.33% |
| ROE | -136.98% |
| Debt/Equity | 2.43 |
|---|---|
| Net debt/EBITDA | -1.75 |
| Current ratio | 2.48 |
| Quick ratio | 2.12 |